MannKind Corporation's Upcoming Presentation at a Major Healthcare Event
MannKind Corporation (NASDAQ: MNKD) is set to make its mark at the Jefferies London Healthcare Conference, where Michael Castagna, the Chief Executive Officer, along with Chris Prentiss, the Chief Financial Officer, will present updates about the company's ongoing efforts in biopharmaceutical innovation.
Presentation Details
The presentation is scheduled for Wednesday, and attendees can look forward to insights starting at 6:30 am ET/11:30 am GMT. This event represents a significant opportunity for MannKind to reach a diverse audience, sharing their commitment to transforming treatments in chronic disease management.
About MannKind Corporation
MannKind Corp is dedicated to advancing chronic disease care through patient-centered solutions. The company focuses on developing treatments that cater to unmet medical needs in areas such as cardiometabolic and orphan lung diseases, striving to address critical conditions such as diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Innovative Drug-Device Combinations
With a strong emphasis on enhancing the quality of life for patients, MannKind specializes in drug-device combinations that seamlessly integrate into daily routines. This approach reflects their ongoing dedication to creating therapies that are not only effective but also convenient for users.
Accessing the Presentation
For those interested in following MannKind's progress, there will be a live audio webcast available on their official website. Additionally, recorded versions will remain accessible for about 90 days post-conference, allowing everyone the chance to catch up on essential updates from MannKind.
Company Contact Information
Individuals interested in more information can reach out to MannKind's Investor Relations through Ana Kapor at ir@mnkd.com. For media inquiries, Christie Iacangelo can be contacted at media@mnkd.com.
Frequently Asked Questions
What is the focus of MannKind Corporation?
MannKind focuses on developing innovative treatments for chronic diseases, particularly in cardiometabolic and orphan lung diseases.
Where will MannKind present updates?
MannKind will present at the Jefferies London Healthcare Conference.
Who will represent MannKind at the conference?
Michael Castagna, the CEO, and Chris Prentiss, the CFO, will represent MannKind during the presentation.
How can I listen to the presentation?
The presentation will be available via live audio webcast on MannKind's official website.
How long will the recorded presentation be available?
Recorded versions will be accessible for approximately 90 days following the conference.